Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
new york blog main
8
×
clinical trials
boston blog main
new york top stories
san francisco blog main
boston top stories
san francisco top stories
cancer
fda
national top stories
deals
europe blog main
europe top stories
investing
ipo
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
startups
biogen
biotech ipos
boston
boulder/denver blog main
boulder/denver top stories
cancer drugs
cancer immunotherapy
deerfield management
detroit blog main
detroit top stories
dihydroergotamine
drug discovery
gilead sciences
indiana blog main
indiana top stories
medical device
melinta therapeutics
What
ipo
8
×
medicines
biotech
companies
ipos
new
activity
bio
covid
days
drug
experimental
hasn’t
life
roundup
satsuma
science
slowed
springworks
street
wall
week
welcomed
acquisitions
ago
announced
approvals
arrival
based
begin
biogen
biosciences
biotechs
bio’s
boost
brings
bubbles
cells
ceo
clamped
Language
unset
8
×
Current search:
ipo
×
unset
×
" new york blog main "
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs